Industry Outlook
The plasma fractionation market at a compound annual growth rate (CAGR) of 7.1% during the forecast period from 2025 to 2033. Plasma fractionation is utilized for achieving large quantities of purified protein from human plasma. Researchers have been focusing diligently in understanding the role and significance of plasma derived proteins in treating chronic ailments and autoimmune diseases. Increasing demand for biologics and increasing healthcare expenditure for drug development activities together drive the plasma fractionation market growth.
Rising prevalence of autoimmune disorders and technical innovation in deriving highly purified proteins from human plasma drive the immunoglobulin market growth
Immunoglobulin are reigning the product segment for plasma fractionation market. Technical innovations in deriving highly purified proteins from human plasma and rising prevalence of autoimmune disorders drive the immunoglobulin market growth. They are primarily of 5 classes (D,G,M,A,E) and several subclasses, responsible for consolidating the immune system. Albumin is gaining huge attention among researchers owing to its drug binding properties and its effective use as drug formulating agent, medical device coating, surgery sealants and vaccine ingredient.
Increasing morbidity and lack of effective biological treatment drive the neurology applications market growth
According to World Health Organization (WHO), approximately 450 million people are reported annually to be suffering with mental illness. Neurology is dominating the application segment for plasma fractionation market. The chief attributes governing its market growth are increasing morbidity and lack of effective biological treatment for neurological disorders. Recently newer antibodies have been developed to hinder the process of protein clusters misfolding which causes Alzheimer’s and Parkinson’s disease. Immunology application will be the fastest growing segment in the near future owing to the significant rise in immunocompromised patients and technological advancement in the development of immunoglobulin to counteract disease manifestations associated with immunosuppression.
Increasing number of patients suffering with chronic disease and presence of state of the art healthcare infrastructure drive the market growth in North America
North America is the supreme leader in global plasma fractionation market representing 38% share. The dominance is attributed to major factors such as increasing number of patients suffering with chronic diseases and presence of state of the art healthcare infrastructure. As per the statistics provided by Center for Disease Control and Prevention (CDC), 1 in every 6 American is living with chronic disease. Europe holds 25% market share owing to the existence of key players such as Biotest AG, Sanquin, Octapharma AG, Grifols, S.A. and supportive regulatory environment provided by the European Medical Agency (EMA). Asia Pacific is responsible for 17% share and will showcase impressive growth during the forecast period on account of rise in per capital income and affordable reimbursement scenario for plasma fractionation products utilized during treatment of chronic ailments.
Biopharmaceuticals actively engaged in providing plasma fractionation products are Baxter International, Inc., Biotest AG., CSL Limited, Grifols, S.A., Green Cross Corporation, Japan Blood Products Organization, Kedrion Biopharma, Inc., Octapharma AG., Sanquin and Shire, Plc.
Historical & Forecast Period
This study report represents analysis of each segment from 2023 to 2033 considering 2024 as the base year. Compounded Annual Growth Rate (CAGR) for each of the respective segments estimated for the forecast period of 2025 to 2033.
The current report comprises of quantitative market estimations for each micro market for every geographical region and qualitative market analysis such as micro and macro environment analysis, market trends, competitive intelligence, segment analysis, porters five force model, top winning strategies, top investment markets, emerging trends and technological analysis, case studies, strategic conclusions and recommendations and other key market insights.
Research Methodology
The complete research study was conducted in three phases, namely: secondary research, primary research, and expert panel review. key data point that enables the estimation of Plasma Fractionation market are as follows:
Market forecast was performed through proprietary software that analyzes various qualitative and quantitative factors. Growth rate and CAGR were estimated through intensive secondary and primary research. Data triangulation across various data points provides accuracy across various analyzed market segments in the report. Application of both top down and bottom-up approach for validation of market estimation assures logical, methodical and mathematical consistency of the quantitative data.
ATTRIBUTE | DETAILS |
---|---|
Research Period | 2023-2033 |
Base Year | 2024 |
Forecast Period | 2025-2033 |
Historical Year | 2023 |
Unit | USD Million |
Segmentation | |
Product
| |
Application
| |
Region Segment (2023-2033; US$ Million)
|
Key questions answered in this report